EVT-201
EVT-201 is a pharmaceutical compound that has been investigated for its potential use in the treatment of insomnia. It is classified as a GABAA receptor modulator, which means it works by enhancing the activity of the gamma-aminobutyric acid (GABA) neurotransmitter in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its modulation can lead to sedative and anxiolytic effects.
Mechanism of Action[edit | edit source]
EVT-201 functions by binding to the benzodiazepine site on the GABAA receptor. This binding increases the receptor's affinity for GABA, thereby enhancing its inhibitory effects. This action results in a calming effect on the brain, which can help to induce and maintain sleep.
Clinical Trials[edit | edit source]
EVT-201 has undergone several clinical trials to evaluate its efficacy and safety in treating insomnia. These trials have shown that EVT-201 can significantly reduce the time it takes for patients to fall asleep and increase the duration of sleep. However, like many GABAA receptor modulators, it may have side effects such as drowsiness, dizziness, and potential for dependence.
Potential Benefits[edit | edit source]
One of the potential benefits of EVT-201 over traditional benzodiazepines and non-benzodiazepine sleep aids is its reduced potential for tolerance and dependence. This makes it a promising candidate for long-term treatment of chronic insomnia.
Related Compounds[edit | edit source]
EVT-201 is related to other GABAA receptor modulators such as zolpidem, eszopiclone, and zaleplon. These compounds also work by enhancing the activity of GABA but may differ in their pharmacokinetic profiles and side effect profiles.
Current Status[edit | edit source]
As of the latest updates, EVT-201 is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Further studies are needed to fully understand its long-term safety and efficacy.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
